Vol 4, No 6 (2024)

Reimbursement Recommendations

Aflibercept 8 mg/0.07 mL (Eylea HD)

CADTH

Published June 21, 2024

PDF HTML

Aflibercept 8 mg/0.07 mL (Eylea HD)

CADTH

Published June 21, 2024

PDF HTML

Epcoritamab (Epkinly)

CADTH

Published June 18, 2024

PDF HTML

Elranatamab (Elrexfio)

CADTH

Published June 18, 2024

PDF HTML

Nivolumab (Opdivo)

CADTH

Published June 14, 2024

PDF HTML

Insulin Icodec (Awiqli)

CADTH

Published June 5, 2024

PDF HTML

Bimekizumab (Bimzelx)

CADTH

Published June 4, 2024

PDF HTML

Bimekizumab (Bimzelx)

CADTH

Published June 3, 2024

PDF HTML

Reimbursement Reviews

Cannabidiol (Epidiolex)

CADTH

Published June 26, 2024

PDF HTML

Ravulizumab (Ultomiris)

CADTH

Published June 13, 2024

PDF HTML

Trifluridine-Tipiracil (Lonsurf)

CADTH

Published June 13, 2024

PDF HTML

Treosulfan (Trecondyv)

CADTH

Published June 7, 2024

PDF HTML

Fidanacogene Elaparvovec (Beqvez)

CADTH

Published June 7, 2024

PDF HTML

Health Technology Review Recommendation

Advisory Panel Guidance on Minimum Retesting Intervals for Lab Tests

CADTH

Published June 11, 2024

PDF HTML

Health Technology Reviews

Choline Supplementation for Infants, Children, and Pregnant People

CADTH

Published June 17, 2024

PDF HTML

Interferons, Glatiramer Acetate, and Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome

CADTH

Published June 13, 2024

PDF HTML

Infliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities

CADTH

Published June 11, 2024

PDF HTML

View All Issues